We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at ...

Biohaven (NYSE:BHVN) shares traded higher on Wednesday after the company said its antibody-drug conjugate BHV-1510 with ...

NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life ...

Pfizer said it would pay $148.50 a share in cash for the Biohaven shares that it doesn’t already own, a nearly 79% premium to Monday’s closing price of $83.14 for the New Haven, Conn., ...

Biohaven plans to submit a New Drug Application (NDA) to the FDA in the fourth quarter of 2024. Biohaven will be prepared to commercialize SCA in the US in 2025, if ultimately approved ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...

May 29, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life ...

As a reminder, Biohaven Ltd. is a British Virgin Islands domiciled, New Haven, Connecticut headquartered clinical-stage biopharmaceutical concern focused on developing treatments for various ...

The last time I wrote about Biohaven (NYSE:BHVN) it was with respect to a Seeking Alpha article entitled "Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst." ...

Sept 23 (Reuters) - Biohaven's (BHVN.N), opens new tab drug for a genetic disease that affects the nervous system met the main study goal, sending its shares up more than 12% as the trial data ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Today, we dig into Biohaven’s plans and see Humira biosimilar ...